Results Evaluating Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma to be Presented at 2019 ASCO Annual Meeting
Dateline City:
KENILWORTH, N.J.
First Randomized Phase 3 Trial Evaluating an Anti-PD-1 Therapy as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of These Patients (KEYNOTE-062)
KENILWORTH, N.J., June 1, 2019 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced full results from the pivotal Phase 3 KEYNOTE-062 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy and in combination with chemotherapy (cisplatin and either 5-fluorouracil or capecitabine) for the first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Language:
English
